At risk from coronavirus, Julian Assange is one of just...<\/h2><\/a>\n READ MORE <\/i><\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n\nAddressing Covid-19<\/strong><\/h2>\n\n\n\nThe Covid-19 crisis demonstrates the need for properly funded and co-ordinated public health systems that are accessible, free to all and are able to prevent and respond to health emergencies. However, as the number of coronavirus cases and deaths is <\/span>set to rise rapidly<\/span><\/a> across the global south in the coming weeks, many public health systems are simply unprepared to deal with the crisis. <\/span><\/p>\n\n\n\nWhile<\/span> the UK has 28 doctors per 10,000 people, even relatively rich developing countries have a small fraction of that, with nine doctors per 10,000 people in South Africa and eight in India. The Central African Republic has only <\/span>three ventilators<\/span><\/a> for a population of five million people. Governments in Angola, C\u00f4te d\u2019Ivoire, Mozambique and South Sudan have <\/span>told the World Health Organisation<\/span><\/a> that they have no intensive care capacity for patients with severe symptoms. <\/span><\/p>\n\n\n\nThe World Bank and other proponents of private healthcare argue that such investments are essential to release pressure from overwhelmed public sectors. However, strong private healthcare systems often weaken government services. Oxfam <\/span>highlights<\/span><\/a> that governments are \u201coften encouraged to provide cash subsidies and tax breaks to attract private providers\u201d, depleting government revenues to invest in public health. <\/span><\/p>\n\n\n\nIn addition, <\/span>healthcare workers<\/span><\/a> are a finite resource and the often more lucrative opportunities in the private sector can draw doctors and nurses away from working for public services. <\/span><\/p>\n\n\n\nIn India, even though some regions, such as left-wing administered <\/span>Kerala<\/span><\/a>, have strong public health systems, there are fears of a dramatic shortage of intensive care beds and ventilators. It has been <\/span>argued<\/span><\/a> that weak support for public sector hospital capacity in India has been exacerbated by the prevalence of private hospitals, with some regions and low-income families at risk of being unable to access key intensive care services during coronavirus. <\/span><\/p>\n\n\n\nStories have already emerged of patients<\/span> being charged eye-watering amounts<\/span><\/a> for testing and treatments in India\u2019s private hospitals. <\/span><\/p>\n\n\n\nMany NGOs <\/span>argue<\/span> that the push for private finance and privatisation in healthcare, coupled with austerity measures and a shrinking public sector in many countries, runs counter to achieving Universal Health Coverage. <\/span>In response to Covid-19, we are already seeing that the market cannot provide equitable health outcomes, but allows those with the resources to stockpile food and pay <\/span>\u201ctriple the market price\u201d<\/span><\/a> for important medical supplies.<\/span><\/p>\n\n\n\nA key risk now is that the private sector approach to health may hinder the development of a coronavirus vaccine that is widely accessible to all. If \u201cmonopoly protection\u201d were to be granted to pharmaceutical companies for new vaccines, this could result in unaffordable prices for millions of people. Pharmaceutical companies could also create barriers for other researchers and companies to prevent using new knowledge and technologies that arise from publicly funded research.<\/span><\/p>\n\n\n\nCampaigners are calling on the British government to ensure that<\/span> \u201cpublic health conditions\u201d<\/span><\/a> are attached to the \u00a3250-million given by the UK for vaccine research to ensure that new vaccines are affordable to the NHS and low-income countries.<\/span><\/p>\n\n\n\nCDC has invested $200m<\/span><\/a> in a company called MedAccess to begin \u201caccelerating access to life-saving medicines, vaccines and diagnostics in Africa and South Asia\u201d. At a time when financialised approaches to public health such as these need to deliver, there has been no announcement on how this investment will support a just response to Covid-19.<\/span><\/p>\n\n\n\n RELATED<\/h3>\n \n \n \n \n <\/a>\n <\/div>\n \n Britain is the WHO\u2019s second biggest state funder \u2013 so...<\/h2><\/a>\n READ MORE <\/i><\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n\nAn \u2018aid for trade\u2019 approach<\/b><\/h2>\n\n\n\n
While the UK government has pledged considerable financial support to developing countries affected by Covid-19, some of its other policies are more questionable. <\/span><\/p>\n\n\n\nEspecially since the 2016 Brexit referendum, aid has increasingly been spent in partnership with the private sector and has been redirected towards sectors and countries where the UK will benefit from future trading relationships. Major international consultancy firms also receive large amounts of money from DFID for project design, management and implementation.<\/span><\/p>\n\n\n\nFor example, DFID recently invested \u00a350-million in a joint advertising campaign with British food and consumer goods corporation Unilever to promote handwashing in developing countries, led by <\/span>\u201chygiene brands Domestos bleach and Lifebuoy soap\u201d<\/span><\/a>. <\/span><\/p>\n\n\n\nThere is also the government\u2019s <\/span>Global Better Health Programme<\/span><\/a>, which will invest \u00a379-million in the private sector to improve health systems in middle-income countries, and which is focused on countries where UK companies are best placed to <\/span>increase their exports<\/span><\/a>. The project delivery partners include PriceWaterhouseCoopers and McKinsey UK.<\/span><\/p>\n\n\n\nOne of the companies poised to benefit from the programme is Healthcare UK \u2013 the export arm of the National Health Service \u2013 which has \u201c<\/span>supported NHS organisations to win export business of more than \u00a3100-million over the last two years\u201d, the government states<\/span>.<\/span><\/p>\n\n\n\nWhat is the alternative?<\/strong><\/h2>\n\n\n\nWhile Covid-19 is an almost unprecedented global crisis, the necessary responses to public health emergencies are well understood. Just as Bevan and his colleagues understood that large-scale public investment in the NHS was vital in the wake of the Second World War, national governments and investors must now re-examine how they can achieve Universal Health Coverage by financing <\/span>strong public health systems<\/span><\/a>.<\/span><\/p>\n\n\n\nAll UK aid must be spent in the interests of public health, not private profit, by contributing to free, universal healthcare and a coronavirus vaccine accessible and affordable to all. UK and multilateral aid should invest more in the public health budgets of national governments.<\/span><\/p>\n\n\n\nOxfam has called for 10 million<\/span><\/a> new healthcare workers and the requisitioning of private-sector health facilities to be put into public service immediately, as Spain has done. In addition, we need nothing less than a rewriting of some of the financial rules of the global economy. There have been calls for a special coronavirus wealth tax to raise funds from those who will profit from the crisis, while African leaders have <\/span>called<\/span><\/a> for debts worth \u00a3100-billion to be cancelled.<\/span><\/p>\n\n\n\nCoronavirus offers the lesson that the market alone is incapable of fulfilling universal public health needs. We have an opportunity to reimagine a world where good health is seen as a universal right, and investment decisions are made on the basis of human well-being, not rate of return. <\/span><\/p>\n\n\n\n
\n\n\n\n
The Covid-19 crisis demonstrates the need for properly funded and co-ordinated public health systems that are accessible, free to all and are able to prevent and respond to health emergencies. However, as the number of coronavirus cases and deaths is <\/span>set to rise rapidly<\/span><\/a> across the global south in the coming weeks, many public health systems are simply unprepared to deal with the crisis. <\/span><\/p>\n\n\n\n While<\/span> the UK has 28 doctors per 10,000 people, even relatively rich developing countries have a small fraction of that, with nine doctors per 10,000 people in South Africa and eight in India. The Central African Republic has only <\/span>three ventilators<\/span><\/a> for a population of five million people. Governments in Angola, C\u00f4te d\u2019Ivoire, Mozambique and South Sudan have <\/span>told the World Health Organisation<\/span><\/a> that they have no intensive care capacity for patients with severe symptoms. <\/span><\/p>\n\n\n\n The World Bank and other proponents of private healthcare argue that such investments are essential to release pressure from overwhelmed public sectors. However, strong private healthcare systems often weaken government services. Oxfam <\/span>highlights<\/span><\/a> that governments are \u201coften encouraged to provide cash subsidies and tax breaks to attract private providers\u201d, depleting government revenues to invest in public health. <\/span><\/p>\n\n\n\n In addition, <\/span>healthcare workers<\/span><\/a> are a finite resource and the often more lucrative opportunities in the private sector can draw doctors and nurses away from working for public services. <\/span><\/p>\n\n\n\n In India, even though some regions, such as left-wing administered <\/span>Kerala<\/span><\/a>, have strong public health systems, there are fears of a dramatic shortage of intensive care beds and ventilators. It has been <\/span>argued<\/span><\/a> that weak support for public sector hospital capacity in India has been exacerbated by the prevalence of private hospitals, with some regions and low-income families at risk of being unable to access key intensive care services during coronavirus. <\/span><\/p>\n\n\n\n Stories have already emerged of patients<\/span> being charged eye-watering amounts<\/span><\/a> for testing and treatments in India\u2019s private hospitals. <\/span><\/p>\n\n\n\n Many NGOs <\/span>argue<\/span> that the push for private finance and privatisation in healthcare, coupled with austerity measures and a shrinking public sector in many countries, runs counter to achieving Universal Health Coverage. <\/span>In response to Covid-19, we are already seeing that the market cannot provide equitable health outcomes, but allows those with the resources to stockpile food and pay <\/span>\u201ctriple the market price\u201d<\/span><\/a> for important medical supplies.<\/span><\/p>\n\n\n\n A key risk now is that the private sector approach to health may hinder the development of a coronavirus vaccine that is widely accessible to all. If \u201cmonopoly protection\u201d were to be granted to pharmaceutical companies for new vaccines, this could result in unaffordable prices for millions of people. Pharmaceutical companies could also create barriers for other researchers and companies to prevent using new knowledge and technologies that arise from publicly funded research.<\/span><\/p>\n\n\n\n Campaigners are calling on the British government to ensure that<\/span> \u201cpublic health conditions\u201d<\/span><\/a> are attached to the \u00a3250-million given by the UK for vaccine research to ensure that new vaccines are affordable to the NHS and low-income countries.<\/span><\/p>\n\n\n\n CDC has invested $200m<\/span><\/a> in a company called MedAccess to begin \u201caccelerating access to life-saving medicines, vaccines and diagnostics in Africa and South Asia\u201d. At a time when financialised approaches to public health such as these need to deliver, there has been no announcement on how this investment will support a just response to Covid-19.<\/span><\/p>\n\n\n While the UK government has pledged considerable financial support to developing countries affected by Covid-19, some of its other policies are more questionable. <\/span><\/p>\n\n\n\n Especially since the 2016 Brexit referendum, aid has increasingly been spent in partnership with the private sector and has been redirected towards sectors and countries where the UK will benefit from future trading relationships. Major international consultancy firms also receive large amounts of money from DFID for project design, management and implementation.<\/span><\/p>\n\n\n\n For example, DFID recently invested \u00a350-million in a joint advertising campaign with British food and consumer goods corporation Unilever to promote handwashing in developing countries, led by <\/span>\u201chygiene brands Domestos bleach and Lifebuoy soap\u201d<\/span><\/a>. <\/span><\/p>\n\n\n\n There is also the government\u2019s <\/span>Global Better Health Programme<\/span><\/a>, which will invest \u00a379-million in the private sector to improve health systems in middle-income countries, and which is focused on countries where UK companies are best placed to <\/span>increase their exports<\/span><\/a>. The project delivery partners include PriceWaterhouseCoopers and McKinsey UK.<\/span><\/p>\n\n\n\n One of the companies poised to benefit from the programme is Healthcare UK \u2013 the export arm of the National Health Service \u2013 which has \u201c<\/span>supported NHS organisations to win export business of more than \u00a3100-million over the last two years\u201d, the government states<\/span>.<\/span><\/p>\n\n\n\n While Covid-19 is an almost unprecedented global crisis, the necessary responses to public health emergencies are well understood. Just as Bevan and his colleagues understood that large-scale public investment in the NHS was vital in the wake of the Second World War, national governments and investors must now re-examine how they can achieve Universal Health Coverage by financing <\/span>strong public health systems<\/span><\/a>.<\/span><\/p>\n\n\n\n All UK aid must be spent in the interests of public health, not private profit, by contributing to free, universal healthcare and a coronavirus vaccine accessible and affordable to all. UK and multilateral aid should invest more in the public health budgets of national governments.<\/span><\/p>\n\n\n\n Oxfam has called for 10 million<\/span><\/a> new healthcare workers and the requisitioning of private-sector health facilities to be put into public service immediately, as Spain has done. In addition, we need nothing less than a rewriting of some of the financial rules of the global economy. There have been calls for a special coronavirus wealth tax to raise funds from those who will profit from the crisis, while African leaders have <\/span>called<\/span><\/a> for debts worth \u00a3100-billion to be cancelled.<\/span><\/p>\n\n\n\n Coronavirus offers the lesson that the market alone is incapable of fulfilling universal public health needs. We have an opportunity to reimagine a world where good health is seen as a universal right, and investment decisions are made on the basis of human well-being, not rate of return. <\/span><\/p>\n\n\n\nRELATED<\/h3>\n
Britain is the WHO\u2019s second biggest state funder \u2013 so...<\/h2><\/a>\n READ MORE <\/i><\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n\n
An \u2018aid for trade\u2019 approach<\/b><\/h2>\n\n\n\n
What is the alternative?<\/strong><\/h2>\n\n\n\n
\n\n\n\n